22-GI-129-EI: XL092-303, A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer

Grants and Contracts Details

StatusActive
Effective start/end date3/29/233/28/25

Funding

  • Exelixis Inc.: $120,769.00